William G Richards
Overview
Explore the profile of William G Richards including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
8683
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paajanen J, Richards W, Xie Y, Mazzola E, Sidopoulos K, Kuckelman J, et al.
Ann Surg
. 2025 Jan;
PMID: 39813065
Objective: We hypothesize that recurrence following pleurectomy decortication (PD) is primarily local. We explored factors associated with tumor recurrence patterns, disease-free interval (DFI), and post-recurrence survival (PRS). Summary Background Data:...
2.
Opitz I, Lauk O, Werner R, Matter A, Hebeisen M, Battilana B, et al.
Ann Thorac Surg
. 2024 Oct;
PMID: 39447855
Background: Pleural mesothelioma (PM) is a cancer with a usually dismal prognosis. However, long-term survivors do exist. Herein, we analyzed long-term survivors (>5 years after surgery) from high-volume centers around...
3.
Gill R, Richards W, Heiling H, Mazzola E, Hung Y, Seethamraju R, et al.
Eur J Radiol
. 2024 May;
176:111527.
PMID: 38810438
Purpose: To assess the potential of apparent diffusion coefficient (ADC) values derived from diffusion weighted (DW) MRI preoperatively to predict the predominant histologic component among biphasic pleural mesothelioma (PM) tumors....
4.
Paajanen J, Sadek A, Richards W, Xie Y, Mazzola E, Sidopoulos K, et al.
Thorac Cancer
. 2024 Apr;
15(15):1237-1245.
PMID: 38627917
Background: Tumor recurrence remains the main barrier to survival after surgery for pleural mesothelioma (PM). Soluble mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125) are established blood-based biomarkers for monitoring...
5.
Knelson E, Ivanova E, Tarannum M, Campisi M, Lizotte P, Booker M, et al.
Cancer Immunol Res
. 2022 Jun;
10(8):947-961.
PMID: 35678717
Activation of the stimulator of interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding of the mechanism of action of STING...
6.
Yeap B, De Rienzo A, Gill R, Oster M, Dao M, Dao N, et al.
J Thorac Oncol
. 2021 Jul;
16(11):1925-1935.
PMID: 34242791
Introduction: Prognostic models for malignant pleural mesothelioma have been limited to demographics, symptoms, and laboratory values. We hypothesize higher accuracy using both tumor and patient characteristics. The mesothelioma prognostic test...
7.
Gill R, Murphy D, Seethamraju R, Mazzola E, Bueno R, Richards W
Radiol Cardiothorac Imaging
. 2021 Mar;
2(2):e190066.
PMID: 33778549
Purpose: To evaluate the interobserver variability associated with quantitative and qualitative MRI assessments of malignant pleural mesothelioma (MPM). Materials And Methods: Patients with MPM who underwent uniform-protocol preoperative MRI between...
8.
De Rienzo A, Coleman M, Yeap B, Severson D, Wadowski B, Gustafson C, et al.
Cancers (Basel)
. 2021 Feb;
13(3).
PMID: 33540554
Sex differences in incidence, prognosis, and treatment response have been described for many cancers. In malignant pleural mesothelioma (MPM), a lethal disease associated with asbestos exposure, men outnumber women 4...
9.
Lebeau P, Wassef H, Byun J, Platko K, Ason B, Jackson S, et al.
J Clin Invest
. 2020 Nov;
131(2).
PMID: 33211673
Individuals harboring the loss-of-function (LOF) proprotein convertase subtilisin/kexin type 9 Gln152His variation (PCSK9Q152H) have low circulating low-density lipoprotein cholesterol levels and are therefore protected against cardiovascular disease (CVD). This uncleavable...
10.
De Rienzo A, Chirieac L, Hung Y, Severson D, Freyaldenhoven S, Gustafson C, et al.
J Pathol
. 2020 Sep;
253(1):68-79.
PMID: 32944962
BRCA1-associated protein-1 (BAP1) expression is commonly lost in several tumors including malignant pleural mesothelioma (MPM). Presence or absence of immunohistochemical BAP1 nuclear staining in tumor cells is currently used for...